neuro-bio ltd
neuro-bio ltd Company Information
Company Number
08580518
Next Accounts
Sep 2025
Shareholders
susan adele greenfield
kairos venture partners 2 lp
View AllGroup Structure
View All
Industry
Other research and experimental development on natural sciences and engineering
Registered Address
building f5, culham science centre, abingdon, oxfordshire, OX14 3DB
Website
http://neuro-bio.comneuro-bio ltd Estimated Valuation
Pomanda estimates the enterprise value of NEURO-BIO LTD at £1.8m based on a Turnover of £1.5m and 1.18x industry multiple (adjusted for size and gross margin).
neuro-bio ltd Estimated Valuation
Pomanda estimates the enterprise value of NEURO-BIO LTD at £0 based on an EBITDA of £-1.3m and a 5.61x industry multiple (adjusted for size and gross margin).
neuro-bio ltd Estimated Valuation
Pomanda estimates the enterprise value of NEURO-BIO LTD at £0 based on Net Assets of £-402.8k and 1.93x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Neuro-bio Ltd Overview
Neuro-bio Ltd is a live company located in abingdon, OX14 3DB with a Companies House number of 08580518. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in June 2013, it's largest shareholder is susan adele greenfield with a 26.4% stake. Neuro-bio Ltd is a established, small sized company, Pomanda has estimated its turnover at £1.5m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Neuro-bio Ltd Health Check
Pomanda's financial health check has awarded Neuro-Bio Ltd a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 5 areas for improvement. Company Health Check FAQs
2 Strong
3 Regular
5 Weak
Size
annual sales of £1.5m, make it smaller than the average company (£4.4m)
- Neuro-bio Ltd
£4.4m - Industry AVG
Growth
3 year (CAGR) sales growth of 11%, show it is growing at a faster rate (6.7%)
- Neuro-bio Ltd
6.7% - Industry AVG
Production
with a gross margin of 46.6%, this company has a comparable cost of product (46.6%)
- Neuro-bio Ltd
46.6% - Industry AVG
Profitability
an operating margin of -91.5% make it less profitable than the average company (3.6%)
- Neuro-bio Ltd
3.6% - Industry AVG
Employees
with 11 employees, this is below the industry average (46)
11 - Neuro-bio Ltd
46 - Industry AVG
Pay Structure
on an average salary of £64.5k, the company has an equivalent pay structure (£64.5k)
- Neuro-bio Ltd
£64.5k - Industry AVG
Efficiency
resulting in sales per employee of £135.3k, this is equally as efficient (£123.2k)
- Neuro-bio Ltd
£123.2k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Neuro-bio Ltd
- - Industry AVG
Creditor Days
its suppliers are paid after 188 days, this is slower than average (44 days)
- Neuro-bio Ltd
44 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Neuro-bio Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (31 weeks)
0 weeks - Neuro-bio Ltd
31 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 307.3%, this is a higher level of debt than the average (44.4%)
307.3% - Neuro-bio Ltd
44.4% - Industry AVG
NEURO-BIO LTD financials
Neuro-Bio Ltd's latest turnover from December 2023 is estimated at £1.5 million and the company has net assets of -£402.8 thousand. According to their latest financial statements, Neuro-Bio Ltd has 11 employees and maintains cash reserves of £11 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Jun 2016 | Jun 2015 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||
| Other Income Or Grants | |||||||||||
| Cost Of Sales | |||||||||||
| Gross Profit | |||||||||||
| Admin Expenses | |||||||||||
| Operating Profit | |||||||||||
| Interest Payable | |||||||||||
| Interest Receivable | |||||||||||
| Pre-Tax Profit | |||||||||||
| Tax | |||||||||||
| Profit After Tax | |||||||||||
| Dividends Paid | |||||||||||
| Retained Profit | |||||||||||
| Employee Costs | |||||||||||
| Number Of Employees | 11 | 9 | 10 | 12 | 16 | 15 | 11 | 11 | |||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Jun 2016 | Jun 2015 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 35,019 | 54,959 | 84,277 | 170,035 | 269,103 | 304,429 | 344,544 | 65,326 | 61,421 | 63,325 | 50,853 |
| Intangible Assets | 3,767 | 3,767 | 3,767 | ||||||||
| Investments & Other | 2,630 | 2,630 | 2,630 | ||||||||
| Debtors (Due After 1 year) | |||||||||||
| Total Fixed Assets | 37,649 | 57,589 | 86,907 | 170,035 | 269,103 | 304,429 | 344,544 | 69,093 | 65,188 | 67,092 | 50,853 |
| Stock & work in progress | |||||||||||
| Trade Debtors | 10,574 | 78,399 | 274,058 | ||||||||
| Group Debtors | |||||||||||
| Misc Debtors | 145,671 | 219,827 | 193,022 | 254,561 | 356,209 | 275,049 | 262,366 | 87,608 | 106,416 | ||
| Cash | 11,018 | 104,696 | 630,134 | 490,741 | 229,987 | 210,543 | 287,699 | 68,653 | 30,483 | 186,235 | |
| misc current assets | |||||||||||
| total current assets | 156,689 | 324,523 | 823,156 | 745,302 | 596,770 | 485,592 | 550,065 | 156,261 | 136,899 | 264,634 | 274,058 |
| total assets | 194,338 | 382,112 | 910,063 | 915,337 | 865,873 | 790,021 | 894,609 | 225,354 | 202,087 | 331,726 | 324,911 |
| Bank overdraft | |||||||||||
| Bank loan | |||||||||||
| Trade Creditors | 409,422 | 213,401 | 86,867 | 108,183 | 64,309 | 86,903 | 287,152 | 57,362 | 26,577 | 75,826 | 34,030 |
| Group/Directors Accounts | |||||||||||
| other short term finances | |||||||||||
| hp & lease commitments | |||||||||||
| other current liabilities | 187,688 | 176,063 | 434,710 | 47,066 | 124,133 | 112,557 | 55,239 | 77,568 | 23,960 | ||
| total current liabilities | 597,110 | 389,464 | 521,577 | 155,249 | 188,442 | 199,460 | 342,391 | 134,930 | 50,537 | 75,826 | 34,030 |
| loans | 2,142,345 | 1,396,377 | 689,084 | ||||||||
| hp & lease commitments | |||||||||||
| Accruals and Deferred Income | |||||||||||
| other liabilities | 10,658 | 18,213 | 28,061 | 100,000 | 175,000 | ||||||
| provisions | |||||||||||
| total long term liabilities | 2,142,345 | 1,407,035 | 707,297 | 28,061 | 100,000 | 175,000 | |||||
| total liabilities | 597,110 | 2,531,809 | 1,928,612 | 862,546 | 216,503 | 199,460 | 342,391 | 134,930 | 150,537 | 75,826 | 209,030 |
| net assets | -402,772 | -2,149,697 | -1,018,549 | 52,791 | 649,370 | 590,561 | 552,218 | 90,424 | 51,550 | 255,900 | 115,881 |
| total shareholders funds | -402,772 | -2,149,697 | -1,018,549 | 52,791 | 649,370 | 590,561 | 552,218 | 90,424 | 51,550 | 255,900 | 115,881 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Jun 2016 | Jun 2015 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | |||||||||||
| Depreciation | 22,662 | 62,630 | 87,898 | 99,329 | 90,917 | 86,581 | 55,823 | 9,522 | 21,123 | ||
| Amortisation | 3,767 | ||||||||||
| Tax | |||||||||||
| Stock | |||||||||||
| Debtors | -74,156 | 26,805 | -61,539 | -112,222 | 91,734 | 12,683 | 174,758 | 9,209 | 28,017 | -195,659 | 274,058 |
| Creditors | 196,021 | 126,534 | -21,316 | 43,874 | -22,594 | -200,249 | 229,790 | -18,464 | -49,249 | 41,796 | 34,030 |
| Accruals and Deferred Income | 11,625 | -258,647 | 387,644 | -77,067 | 11,576 | 57,318 | -22,329 | 77,568 | 23,960 | ||
| Deferred Taxes & Provisions | |||||||||||
| Cash flow from operations | |||||||||||
| Investing Activities | |||||||||||
| capital expenditure | |||||||||||
| Change in Investments | 2,630 | ||||||||||
| cash flow from investments | |||||||||||
| Financing Activities | |||||||||||
| Bank loans | |||||||||||
| Group/Directors Accounts | |||||||||||
| Other Short Term Loans | |||||||||||
| Long term loans | -2,142,345 | 745,968 | 707,293 | 689,084 | |||||||
| Hire Purchase and Lease Commitments | |||||||||||
| other long term liabilities | -10,658 | -7,555 | -9,848 | 28,061 | 100,000 | -175,000 | 175,000 | ||||
| share issue | |||||||||||
| interest | |||||||||||
| cash flow from financing | |||||||||||
| cash and cash equivalents | |||||||||||
| cash | -93,678 | -525,438 | 139,393 | 260,754 | 19,444 | -77,156 | 219,046 | -117,582 | -155,752 | 186,235 | |
| overdraft | |||||||||||
| change in cash | -93,678 | -525,438 | 139,393 | 260,754 | 19,444 | -77,156 | 219,046 | -117,582 | -155,752 | 186,235 |
neuro-bio ltd Credit Report and Business Information
Neuro-bio Ltd Competitor Analysis
Perform a competitor analysis for neuro-bio ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in OX14 area or any other competitors across 12 key performance metrics.
neuro-bio ltd Ownership
NEURO-BIO LTD group structure
Neuro-Bio Ltd has no subsidiary companies.
Ultimate parent company
NEURO-BIO LTD
08580518
neuro-bio ltd directors
Neuro-Bio Ltd currently has 4 directors. The longest serving directors include Baroness Susan Greenfield (Jun 2013) and Mr David Fuente (Mar 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Baroness Susan Greenfield | England | 74 years | Jun 2013 | - | Director |
| Mr David Fuente | England | 79 years | Mar 2017 | - | Director |
| Mr Todd Thomson | England | 64 years | Jun 2020 | - | Director |
| Mr William Anderson | 59 years | Jan 2025 | - | Director |
P&L
December 2023turnover
1.5m
+42%
operating profit
-1.4m
0%
gross margin
46.7%
-1.1%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
-402.8k
-0.81%
total assets
194.3k
-0.49%
cash
11k
-0.89%
net assets
Total assets minus all liabilities
Similar Companies
neuro-bio ltd company details
company number
08580518
Type
Private limited with Share Capital
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
June 2013
age
12
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
-
address
building f5, culham science centre, abingdon, oxfordshire, OX14 3DB
Bank
-
Legal Advisor
-
neuro-bio ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to neuro-bio ltd.
neuro-bio ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NEURO-BIO LTD. This can take several minutes, an email will notify you when this has completed.
neuro-bio ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
